Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 216

Results For "RI"

11152 News Found

Lupin signs MoU with Govt. of Maharashtra to combat rising prevalence of cardiovascular diseases
News | June 21, 2023

Lupin signs MoU with Govt. of Maharashtra to combat rising prevalence of cardiovascular diseases

The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence


Nouryon launches new high-efficiency spherical silica for peptide-based pharmaceuticals
News | June 21, 2023

Nouryon launches new high-efficiency spherical silica for peptide-based pharmaceuticals

This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments


Quantiphi join hands with Pharmarack and Snowflake to drive AI based innovation
Digitisation | June 21, 2023

Quantiphi join hands with Pharmarack and Snowflake to drive AI based innovation

This partnership will revolutionize Pharmarack's digital infrastructure with Snowflake's single, integrated platform to facilitate advanced analytic


DGCI grants Emergency Use Authorisation to Gennova mRNA Covid booster vaccine
News | June 21, 2023

DGCI grants Emergency Use Authorisation to Gennova mRNA Covid booster vaccine

The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield


Biostar Pharma receives FDA approval Utidelone Injectable Phase 2/3 clinical trial for cell lung cancer
Drug Approval | June 20, 2023

Biostar Pharma receives FDA approval Utidelone Injectable Phase 2/3 clinical trial for cell lung cancer

This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable


Zydus receives final approval from the USFDA for Minocycline Hydrochloride ER Tablets
Drug Approval | June 20, 2023

Zydus receives final approval from the USFDA for Minocycline Hydrochloride ER Tablets

The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.


Lupin launches Thiamine Hydrochloride Injection USP in the US
Drug Approval | June 19, 2023

Lupin launches Thiamine Hydrochloride Injection USP in the US

Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.


Alkem Laboratories launches awareness initiative
News | June 19, 2023

Alkem Laboratories launches awareness initiative "Stop Sneeze to Wheeze"

Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis


Lupin receives EIR from FDA for its API manufacturing facility in Vizag
Drug Approval | June 19, 2023

Lupin receives EIR from FDA for its API manufacturing facility in Vizag

The inspection closed with the facility receiving an inspection classification of NAI


Pembrolizumab + Trastuzumab and chemotherapy met primary endpoint as first line of treatment for GEJ
News | June 17, 2023

Pembrolizumab + Trastuzumab and chemotherapy met primary endpoint as first line of treatment for GEJ

Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma